Home › Funds › Kynam Capital Management, LP › CLDX
Kynam Capital Management, LP position in CLDX
CELLDEX THERAPEUTICS INC NEW · Health Care
Kynam Capital Management, LP reported holding 5,322,908 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q2 2026 13F filing — a position valued at US$198.1M, representing 10.95% of its reported portfolio and ranking #1 among its reported holdings. Kynam Capital Management, LP has disclosed CLDX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Kynam Capital Management, LP's CLDX position evolved
Kynam Capital Management, LP first disclosed a stake in CLDX in Q3 2023 at 3,200,000 shares (US$88.1M). The position peaked in Q2 2026 at 5,322,908 shares, worth US$198.1M. Across 12 filings, Kynam Capital Management, LP increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 5,322,908 shares valued at US$198.1M — a reduction of -517,659 shares quarter over quarter.. Notable position changes include a 46% increase in Q4 2024 (shares fell 28% over the following quarter), a 28% increase in Q1 2025 (shares rose 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.20M | $88.06M | New |
| Q4 2023 | 3.01M | $119.21M | Reduce |
| Q1 2024 | 2.90M | $121.71M | Reduce |
| Q2 2024 | 3.39M | $125.43M | Add |
| Q3 2024 | 3.46M | $117.56M | Add |
| Q4 2024 | 5.06M | $127.97M | Add |
| Q1 2025 | 6.50M | $117.97M | Add |
| Q2 2025 | 6.10M | $124.15M | Reduce |
| Q3 2025 | 6.10M | $157.83M | Hold |
| Q4 2025 | 5.94M | $161.42M | Reduce |
| Q1 2026 | 5.84M | $185.26M | Reduce |
| Q2 2026 | 5.32M | $198.07M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLDX and 13F data
CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 43 other funds we track also report a position in CLDX — the largest reported positions include Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M), Eversept Partners, LP (US$66.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLDX
- Deep Track Capital, LP 2.94M sh · $109.37M · Q2 2026
- Logos Global Management LP 2.10M sh · $78.14M · Q2 2026
- Eversept Partners, LP 1.79M sh · $66.45M · Q2 2026
- Commodore Capital LP 1.35M sh · $50.23M · Q2 2026
- Bellevue Group AG 1.20M sh · $44.65M · Q2 2026
- BAKER BROS. ADVISORS LP 1.18M sh · $44.00M · Q2 2026
- Novo Holdings A/S 1.02M sh · $38.14M · Q2 2026
- Elmind Capital, LP 990.00K sh · $36.84M · Q2 2026
- Foresite Capital Management VI LLC 879.71K sh · $32.73M · Q2 2026
- Affinity Asset Advisors, LLC 700.00K sh · $26.05M · Q2 2026
- Rock Springs Capital Management LP 699.15K sh · $26.02M · Q2 2026
- ADAR1 Capital Management, LLC 619.54K sh · $23.05M · Q2 2026
More on Kynam Capital Management, LP
FAQ
How long has Kynam Capital Management, LP held CLDX?
Kynam Capital Management, LP has disclosed CLDX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Kynam Capital Management, LP's current position in CLDX?
As of Q2 2026, Kynam Capital Management, LP holds 5.32M shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $198.07M, representing 10.95% of its reported portfolio and ranking #1.
Has Kynam Capital Management, LP been buying or selling CLDX?
In the latest 13F filing (Q2 2026), Kynam Capital Management, LP reduced its position in CLDX. The position peaked in Q2 2026 at 5.32M shares.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Deep Track Capital, LP, Logos Global Management LP, Eversept Partners, LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.